Did you mean amitifadine of en 10 of dov 21,947 of アミティファジン?
Displaying drugs 701 - 725 of 8873 in total
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … rupture in which the layers of the vessel separate prior to complete failure of the artery wall). ... This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Lorazepam
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Fenofibric acid
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of …
Nabumetone
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate ... [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone …
Crizanlizumab
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … of reducing morbidity and mortality. ... Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive ... disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … relapsed of refractory acute myeloid leukemia in adults. ... [A248745]
Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of ... A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of …
Nabilone
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … , a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. ... psychoactive component of cannabis (marijuana). ... Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers. …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as ... In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological ... well as the treatment of acromegaly. …
Melphalan flufenamide
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. ... [A230123] _In vitro_ models show that melphalan is 10 to hundreds of times more potent than melphalan ... option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of …
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid ... [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available …
Sulconazole
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of cilgavimab does not overlap with that of [tixagevimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
Vaborbactam
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … varying degrees of renal insufficiency. ... Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with …
Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Description: … Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast ... converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of …
Peginterferon beta-1a
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of...
Approved
Matched Description: … forms of MS. ... [L5801] MS is one of the most common causes of neurological disability in young adults and is found to ... 20 to 40, often the most productive years of life. …
Vernakalant
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of …
Lorpiprazole
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …
Thiosulfuric acid
Thiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has a variety of industrial uses, including food preservative, water de-chlorinator and paper pulp bleaching agent. Sodium thiosulfate is rapidly degraded...
Approved
Investigational
Matched Description: … Sodium thiosulfate is part of the World Health Organization’s list of essential medicines, and it has ... Sodium thiosulfate is also used to reduce the risk of ototoxicity associated with [cisplatin]. ... ] and it is frequently used in conjunction with sodium nitrite (a salt form of [nitrous acid]). …
Apraclonidine
Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
Approved
Loxoprofen
Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
Approved
Lemborexant
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … a new wave of treatment options for patients suffering from insomnia. ... Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized ... [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven …
Tyrothricin
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis [L4019, L4021, A32851] which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus . This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1,...
Approved
Matched Description: … This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely ... of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors) and ... microbial resistance during the over 60 years of therapeutic use the complex has provided [A36360]. …
Plasminogen
Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of ... approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of ... pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of …
Displaying drugs 701 - 725 of 8873 in total